[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @PTarantinoMD Paolo Tarantino Paolo Tarantino posts on X about all the, $fro, delta, breast cancer the most. They currently have XXXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours. ### Engagements: XXXXX [#](/creator/twitter::958742483856486400/interactions)  - X Week XXXXXX +166% - X Month XXXXXXX +507% - X Months XXXXXXX -XX% - X Year XXXXXXXXX +0.31% ### Mentions: XX [#](/creator/twitter::958742483856486400/posts_active)  ### Followers: XXXXXX [#](/creator/twitter::958742483856486400/followers)  - X Week XXXXXX +0.57% - X Month XXXXXX +1.60% - X Months XXXXXX +8.80% - X Year XXXXXX +18% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::958742483856486400/influencer_rank)  ### Social Influence [#](/creator/twitter::958742483856486400/influence) --- **Social category influence** [technology brands](/list/technology-brands) X% **Social topic influence** [all the](/topic/all-the) 5%, [$fro](/topic/$fro) 5%, [delta](/topic/delta) 5%, [breast cancer](/topic/breast-cancer) #37 **Top accounts mentioned or mentioned by** [@kennakoehler](/creator/undefined) [@fedrophd](/creator/undefined) [@breastcancerstd](/creator/undefined) [@dryukselurun](/creator/undefined) [@vitti10](/creator/undefined) [@drhburstein](/creator/undefined) [@curijoey](/creator/undefined) [@ccortimd](/creator/undefined) [@esmoopen](/creator/undefined) [@pablomando](/creator/undefined) [@myesmo](/creator/undefined) [@helenadecosta1](/creator/undefined) [@gilesgeddes](/creator/undefined) [@mpishvaian](/creator/undefined) [@eva_lpr](/creator/undefined) [@medicalwatchhq](/creator/undefined) [@larvol](/creator/undefined) [@medwatchkate](/creator/undefined) [@notgenentech](/creator/undefined) **Top assets mentioned** [Frontline Ltd. (FRO)](/topic/$fro) ### Top Social Posts [#](/creator/twitter::958742483856486400/posts) --- Top posts by engagements in the last XX hours "Here you go ⚡" [X Link](https://x.com/PTarantinoMD/status/1969184815388807264) [@PTarantinoMD](/creator/x/PTarantinoMD) 2025-09-19T23:40Z 29.5K followers, 17K engagements "Wow. All the benefit of checkpoint inhibition in A-BRAVE (high-risk TNBC) was seen in patients with TILs 30%. No benefit with low TILs. Unbelievable that we didnt get to see the TILs data from KN522 yet. Hope well see them soon. Congrats @vitti10 #ESMO25 #ESMOAmbassadors" [X Link](https://x.com/PTarantinoMD/status/1979828482499915992) [@PTarantinoMD](/creator/x/PTarantinoMD) 2025-10-19T08:34Z 29.5K followers, 11K engagements "Asian phase X trial of Sac-TMT (Trop2 ADC) vs chemo in pretreated HR+/HER2- MBC. Impressive doubling in PFS (8.3 vs XXX mo) positive OS trend. Compares favorably with data with SG despite similar ADC structure. Phase X testing ongoing in western pts. #ESMO25 #ESMOAmbassadors" [X Link](https://x.com/PTarantinoMD/status/1979475599203942428) [@PTarantinoMD](/creator/x/PTarantinoMD) 2025-10-18T09:12Z 29.4K followers, 4738 engagements "#ESMO25 will bring two new combos for the treatment of HR+/HER2- breast cancer. How would you treat a patient with HR+/HER2- MBC with visceral mets who progresses after XX months on 1L letrozole/ribociclib and is found to have an ESR1 mutation (assuming all available)" [X Link](https://x.com/PTarantinoMD/status/1980147762818859162) [@PTarantinoMD](/creator/x/PTarantinoMD) 2025-10-20T05:43Z 29.4K followers, 9247 engagements "The KM curve of 2025: among high risk patients with HER2+ eBC and RD adjuvant T-DXd halved the risk of recurrence vs T-DM1. New SoC for pts with: -inoperable disease at diagnosis -node-positive RD XXXX% rate of ILD X deaths. Remember to monitor the lungs #ESMOAmbassadors" [X Link](https://x.com/PTarantinoMD/status/1979565393258979341) [@PTarantinoMD](/creator/x/PTarantinoMD) 2025-10-18T15:09Z 29.4K followers, 5186 engagements "One week to #ESMO25. An unprecedented ESMO conference. Seven positive press releases anticipating the expansion of T-DXd to the curative setting two Trop2 ADCs reaching first-line mTNBC X novel ET-based combos adjuvant CDK4/6i improving OS. See you in Berlin #ESMOAmbassadors" [X Link](https://x.com/PTarantinoMD/status/1976244542853808316) [@PTarantinoMD](/creator/x/PTarantinoMD) 2025-10-09T11:13Z 29.5K followers, 32.8K engagements "No time to wrap our head around two practice-changing trials (DB-09 PATINA) that a third innovation joins the frontline setting for HER2+ mBC. HER2CLIMB-05 is positive: tucatinib added to HP maintenance improves PFS. Could it prevent/delay brain mets 🧠" [X Link](https://x.com/PTarantinoMD/status/1978058367361761431) [@PTarantinoMD](/creator/x/PTarantinoMD) 2025-10-14T11:20Z 29.4K followers, 14.2K engagements "1 mg/kg of pembro saturates PD1. Could we give a lower dose and reduce financial tox In the PLANeT randomized ph X trial low dose pembro (50 mg for X Q6W doses) added to neoadjuvant ddAC-T significantly improved pCR for stage II-III TNBC (delta 13%). #ESMO25 #ESMOAmbassadors" [X Link](https://x.com/PTarantinoMD/status/1979164310715670617) [@PTarantinoMD](/creator/x/PTarantinoMD) 2025-10-17T12:35Z 29.5K followers, 13.9K engagements "How do adjuvant CDK4/6i impact the biology of breast cancer that recurs Angie DeMichele highlights our RW study led by @CCortiMD which found XX% of pts losing ER expression and having short 1L PFS if relapsing after abema. Published in @ESMO_Open #ESMO25 #ESMOAmbassadors" [X Link](https://x.com/PTarantinoMD/status/1979177751958487495) [@PTarantinoMD](/creator/x/PTarantinoMD) 2025-10-17T13:28Z 29.4K followers, 12.4K engagements "Impressive results from DB-11 with improvement in pCR rate (67% vs 56%) positive EFS trend & more favorable safety with T-DXd-THP vs ddAC-THP in high risk HER2+ eBC. Benefit mostly seen in N+ patients (90% of the pts). New neoadjuvant treatment option #ESMO25 #ESMOAmbassadors" [X Link](https://x.com/PTarantinoMD/status/1979558764870328586) [@PTarantinoMD](/creator/x/PTarantinoMD) 2025-10-18T14:42Z 29.5K followers, 4305 engagements "The KM curve of 2025 outside of breast oncology. Neoadjuvant EV+pembro more than halved the risk of recurrence and significantly improved OS among platinum-ineligible pts with bladder cancer. The tremendous power of ADCs + IO transforming oncology. #ESMO25 #ESMOAmbassadors" [X Link](https://x.com/PTarantinoMD/status/1979571943268635040) [@PTarantinoMD](/creator/x/PTarantinoMD) 2025-10-18T15:35Z 29.5K followers, 5640 engagements "Such a great day. Two Trop2 ADCs (SG Dato-DXd) just replaced 1L chemo for IO-ineligible mTNBC a huge unmet need. Pros and cons for the choice of each. Dato-DXd though looked safer with no G5 toxicity (vs X deaths with SG). Proactive management of ADC toxicities is key" [X Link](https://x.com/PTarantinoMD/status/1979837169582973355) [@PTarantinoMD](/creator/x/PTarantinoMD) 2025-10-19T09:08Z 29.5K followers, 6698 engagements "A lot of heterogeneity in the management of stage II HER2+ breast cancer. The only consensus - no anthracyclines" [X Link](https://x.com/PTarantinoMD/status/1980520582140879066) [@PTarantinoMD](/creator/x/PTarantinoMD) 2025-10-21T06:24Z 29.4K followers, 3108 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@PTarantinoMD Paolo Tarantino
Paolo Tarantino posts on X about all the, $fro, delta, breast cancer the most. They currently have XXXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.
Engagements: XXXXX #
- X Week XXXXXX +166%
- X Month XXXXXXX +507%
- X Months XXXXXXX -XX%
- X Year XXXXXXXXX +0.31%
Mentions: XX #
Followers: XXXXXX #
- X Week XXXXXX +0.57%
- X Month XXXXXX +1.60%
- X Months XXXXXX +8.80%
- X Year XXXXXX +18%
CreatorRank: XXXXXXXXX #
Social Influence #
Social category influence technology brands X%
Social topic influence all the 5%, $fro 5%, delta 5%, breast cancer #37
Top accounts mentioned or mentioned by @kennakoehler @fedrophd @breastcancerstd @dryukselurun @vitti10 @drhburstein @curijoey @ccortimd @esmoopen @pablomando @myesmo @helenadecosta1 @gilesgeddes @mpishvaian @eva_lpr @medicalwatchhq @larvol @medwatchkate @notgenentech
Top assets mentioned Frontline Ltd. (FRO)
Top Social Posts #
Top posts by engagements in the last XX hours
"Here you go ⚡"
X Link @PTarantinoMD 2025-09-19T23:40Z 29.5K followers, 17K engagements
"Wow. All the benefit of checkpoint inhibition in A-BRAVE (high-risk TNBC) was seen in patients with TILs 30%. No benefit with low TILs. Unbelievable that we didnt get to see the TILs data from KN522 yet. Hope well see them soon. Congrats @vitti10 #ESMO25 #ESMOAmbassadors"
X Link @PTarantinoMD 2025-10-19T08:34Z 29.5K followers, 11K engagements
"Asian phase X trial of Sac-TMT (Trop2 ADC) vs chemo in pretreated HR+/HER2- MBC. Impressive doubling in PFS (8.3 vs XXX mo) positive OS trend. Compares favorably with data with SG despite similar ADC structure. Phase X testing ongoing in western pts. #ESMO25 #ESMOAmbassadors"
X Link @PTarantinoMD 2025-10-18T09:12Z 29.4K followers, 4738 engagements
"#ESMO25 will bring two new combos for the treatment of HR+/HER2- breast cancer. How would you treat a patient with HR+/HER2- MBC with visceral mets who progresses after XX months on 1L letrozole/ribociclib and is found to have an ESR1 mutation (assuming all available)"
X Link @PTarantinoMD 2025-10-20T05:43Z 29.4K followers, 9247 engagements
"The KM curve of 2025: among high risk patients with HER2+ eBC and RD adjuvant T-DXd halved the risk of recurrence vs T-DM1. New SoC for pts with: -inoperable disease at diagnosis -node-positive RD XXXX% rate of ILD X deaths. Remember to monitor the lungs #ESMOAmbassadors"
X Link @PTarantinoMD 2025-10-18T15:09Z 29.4K followers, 5186 engagements
"One week to #ESMO25. An unprecedented ESMO conference. Seven positive press releases anticipating the expansion of T-DXd to the curative setting two Trop2 ADCs reaching first-line mTNBC X novel ET-based combos adjuvant CDK4/6i improving OS. See you in Berlin #ESMOAmbassadors"
X Link @PTarantinoMD 2025-10-09T11:13Z 29.5K followers, 32.8K engagements
"No time to wrap our head around two practice-changing trials (DB-09 PATINA) that a third innovation joins the frontline setting for HER2+ mBC. HER2CLIMB-05 is positive: tucatinib added to HP maintenance improves PFS. Could it prevent/delay brain mets 🧠"
X Link @PTarantinoMD 2025-10-14T11:20Z 29.4K followers, 14.2K engagements
"1 mg/kg of pembro saturates PD1. Could we give a lower dose and reduce financial tox In the PLANeT randomized ph X trial low dose pembro (50 mg for X Q6W doses) added to neoadjuvant ddAC-T significantly improved pCR for stage II-III TNBC (delta 13%). #ESMO25 #ESMOAmbassadors"
X Link @PTarantinoMD 2025-10-17T12:35Z 29.5K followers, 13.9K engagements
"How do adjuvant CDK4/6i impact the biology of breast cancer that recurs Angie DeMichele highlights our RW study led by @CCortiMD which found XX% of pts losing ER expression and having short 1L PFS if relapsing after abema. Published in @ESMO_Open #ESMO25 #ESMOAmbassadors"
X Link @PTarantinoMD 2025-10-17T13:28Z 29.4K followers, 12.4K engagements
"Impressive results from DB-11 with improvement in pCR rate (67% vs 56%) positive EFS trend & more favorable safety with T-DXd-THP vs ddAC-THP in high risk HER2+ eBC. Benefit mostly seen in N+ patients (90% of the pts). New neoadjuvant treatment option #ESMO25 #ESMOAmbassadors"
X Link @PTarantinoMD 2025-10-18T14:42Z 29.5K followers, 4305 engagements
"The KM curve of 2025 outside of breast oncology. Neoadjuvant EV+pembro more than halved the risk of recurrence and significantly improved OS among platinum-ineligible pts with bladder cancer. The tremendous power of ADCs + IO transforming oncology. #ESMO25 #ESMOAmbassadors"
X Link @PTarantinoMD 2025-10-18T15:35Z 29.5K followers, 5640 engagements
"Such a great day. Two Trop2 ADCs (SG Dato-DXd) just replaced 1L chemo for IO-ineligible mTNBC a huge unmet need. Pros and cons for the choice of each. Dato-DXd though looked safer with no G5 toxicity (vs X deaths with SG). Proactive management of ADC toxicities is key"
X Link @PTarantinoMD 2025-10-19T09:08Z 29.5K followers, 6698 engagements
"A lot of heterogeneity in the management of stage II HER2+ breast cancer. The only consensus - no anthracyclines"
X Link @PTarantinoMD 2025-10-21T06:24Z 29.4K followers, 3108 engagements